Efficacy and safety of vismodegib in periocular and orbital basal cell carcinoma: a systematic review and meta-analysis - Takeaways - MDSpire

Efficacy and safety of vismodegib in periocular and orbital basal cell carcinoma: a systematic review and meta-analysis

  • By

  • Dalal Alessa

  • May 11, 2026

  • 0 min

Share

  • 1

    Vismodegib shows a pooled complete response rate of 38.4% and a partial response rate of 39.2% in treating periocular and orbital basal cell carcinoma.

  • 2

    Recurrence rates after discontinuation of vismodegib therapy are significant, reported at 17.4%, indicating challenges in long-term management.

  • 3

    Exenteration was performed in 28.1% of patients despite vismodegib treatment, highlighting the limitations of this therapy.

  • 4

    Adverse events were reported in 90.3% of patients, with common issues including alopecia, muscle spasms, and weight loss.

  • 5

    Careful patient selection and monitoring are crucial for optimizing outcomes with vismodegib in periocular and orbital basal cell carcinoma.

Original Source(s)

Efficacy and safety of vismodegib in periocular and orbital basal cell carcinoma: a systematic review and meta-analysis

  • by Dalal Alessa

  • May 11, 2026

Related Content

Dana-Farber Research News 05.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 16 - 30.

  • by

  • May 15, 2026

  • 21 min
Gene amplification in the premalignant stages of non-small cell lung cancer development

Correction: Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma